Two-step feature selection for predicting survival time of patients with metastatic castrate resistant prostate cancer

Metastatic castrate resistant prostate cancer (mCRPC) is the major cause of death in prostate cancer patients. Even though some options for treatment of mCRPC have been developed, the most effective therapies remain unclear. Thus finding key patient clinical variables related with mCRPC is an import...

Descripción completa

Detalles Bibliográficos
Autor principal: Shiga, Motoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Method Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/
https://www.ncbi.nlm.nih.gov/pubmed/27990267
http://dx.doi.org/10.12688/f1000research.8201.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130083/
https://www.ncbi.nlm.nih.gov/pubmed/27990267
http://dx.doi.org/10.12688/f1000research.8201.1

Ejemplares similares